Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: The CATS randomized trial

European Heart Journal

Volumn 24, Issue 5, 2003, Pages 412-420

  Hillege, H L ^a   Van Gilst, W H ^a,b   Van Veldhuisen, D J ^a   Navis, G ^a   Grobbee, D E ^c   De Graeff, P A ^a,b   De Zeeuw, D ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiotensin converting enzyme inhibitors; Myocardial infarction; Prognosis; Renal function

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STREPTOKINASE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS;

EID: 0037336098     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00526-2     Document Type: Article

References (37)

1. Dries DL, Exner DV, Domanski MJ et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9.
2. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-10.
3. Culleton BF, Larson MG, Evans JC et al. Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study. Arch Intern Med 1999;159: 1785-90.
4. Culleton BF, Larson MG, Wilson PW et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
5. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984;26:861-8.
6. Manttari M, Tiula E, Alikoski T et al. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995;26:670-5.
7. Fliser D, Franek E, Joest M et al. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997;51:1196-204.
8. Krop JS, Coresh J, Chambless LE et al. A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: the Atherosclerosis Risk in Communities study. Arch Intern Med 1999;159:1777-83.
9. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998;97:2202-12.
10. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
11. Knight EL, Glynn RJ, McIntyre KM et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999;138:849-55.
12. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.
13. van Gilst WH, Kingma JH, Peels KH et al. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). J Am Coll Cardiol 1996; 28:114-21.
14. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Luke DR, Halstenson CE, Opsahl JA et al. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther 1990;48:503-8.
16. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629-36.
17. Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
18. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-85.
19. Parving HH, Andersen AR, Smidt UM et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1:1175-9.
20. Motwani JG, Fenwick MK, McAlpine HM et al. Effectiveness of captopril in reversing renal vasoconstriction after Q-wave acute myocardial infarction. Am J Cardiol 1993;71:281-6.
21. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-63.
22. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
23. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.
24. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793-7.
25. McCullough PA, Soman SS, Shah SS et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000;36:679-84.
26. Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13:180-93.
27. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke 1997;28:557-63.
28. Kovar D, Rogers WJ, Ganto JG et al. Poor outcome of patients with chronic renal insufficiency presenting with myocardial infarction. Circulation 2000; 102(Suppl):II-792.
29. Matts JP, Karnegis JN, Campos CT et al. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. J Fam Pract 1993;36:497-503.
30. Hallynck T, Soep HH, Thomis J et al. Prediction of creatinine clearance from serum creatinine concentration based on lean body mass. Clin Pharmacol Ther 1981;30:414-21.
31. Kasiske BL. The kidney in cardiovascular disease. Ann Intern Med 2001;134:707-9.
32. Abildgaard U. Andersen JS, Daugaard G et al. Renal function in patients with untreated acute myocardial infarction. Scand J Clin Lab Invest 1992;52:689-95.
33. Efendigil MC, Harley A, Deegan T et al. Changes in glomerular filtration rate following myocardial infarction. Cardiovasc Res 1975;9:741-4.
34. Laragh JH. Role of renin secretion and kidney function in hypertension and attendant heart attack and stroke. Clin Exp Hypertens A 1992;14:285-305.
35. Klahr S, Morrissey JJ. The role of vasoactive compounds growth factors and cytokines in the progression of renal disease. Kidney Int 2000;57(Suppl. 75):S7-S14.
36. Matsusaka T, Hymes J. Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 1996; 7:2025-43.
37. Matsusaka T, Katori H, Homma T et al. Mechanism of cardiac fibrosis by angiotensin. New insight revealed by genetic engineering. Trends Cardiovasc Med 1999;9:180-4.